- Home
- GOVX vs MTNB Comparison
GOVX vs MTNB Comparison
Compare GOVX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- MTNB
- Stock Information
- Founded
- GOVX 2001
- MTNB 2013
- Country
- GOVX United States
- MTNB United States
- Employees
- GOVX N/A
- MTNB N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- MTNB Health Care
- Exchange
- GOVX Nasdaq
- MTNB Nasdaq
- Market Cap
- GOVX 7.6M
- MTNB 7.9M
- IPO Year
- GOVX N/A
- MTNB N/A
- Fundamental
- Price
- GOVX $0.68
- MTNB $1.79
- Analyst Decision
- GOVX Strong Buy
- MTNB Hold
- Analyst Count
- GOVX 3
- MTNB 1
- Target Price
- GOVX $10.67
- MTNB N/A
- AVG Volume (30 Days)
- GOVX 690.2K
- MTNB 1.4M
- Earning Date
- GOVX 11-11-2025
- MTNB 11-12-2025
- Dividend Yield
- GOVX N/A
- MTNB N/A
- EPS Growth
- GOVX N/A
- MTNB N/A
- EPS
- GOVX N/A
- MTNB N/A
- Revenue
- GOVX $6,143,044.00
- MTNB N/A
- Revenue This Year
- GOVX N/A
- MTNB N/A
- Revenue Next Year
- GOVX N/A
- MTNB N/A
- P/E Ratio
- GOVX N/A
- MTNB N/A
- Revenue Growth
- GOVX 1943.07
- MTNB N/A
- 52 Week Low
- GOVX $0.43
- MTNB $0.47
- 52 Week High
- GOVX $3.88
- MTNB $4.25
- Technical
- Relative Strength Index (RSI)
- GOVX 41.08
- MTNB 55.25
- Support Level
- GOVX $0.65
- MTNB $1.59
- Resistance Level
- GOVX $0.73
- MTNB $1.88
- Average True Range (ATR)
- GOVX 0.04
- MTNB 0.15
- MACD
- GOVX -0.00
- MTNB -0.04
- Stochastic Oscillator
- GOVX 21.28
- MTNB 30.67
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.